Impact of a Recall of Intravitreal Bevacizumab: a Health Analytics in Ophthalmology Registry Review
Ophthalmol Retina
.
2024 Dec;8(12):1211-1213.
doi: 10.1016/j.oret.2024.08.021.
Epub 2024 Sep 2.
Authors
Hasenin Al-Khersan
1
,
Elioenai Garcia
2
,
Kenneth C Fan
3
,
Patrick C Staropoli
3
,
Edward H Wood
4
,
Philip Storey
4
,
Murtaza K Adam
5
,
David W Parke 3rd
6
,
Lawrence S Halperin
7
,
Kevin Quinn
8
,
Charles C Wykoff
3
Affiliations
1
Retina Consultants of Texas, Houston, Texas. Electronic address: hakmd@retinaconsultantstexas.com.
2
University of Texas Medical Branch School of Medicine, Galveston, Texas.
3
Retina Consultants of Texas, Houston, Texas.
4
Austin Retina Associates, Austin, Texas.
5
Colorado Retina Associates, Denver, Colorado.
6
Retina Consultants of Minnesota, Minneapolis, Minnesota.
7
Retina Group of Florida, Fort Lauderdale, Florida.
8
Retina Consultants of America, Southlake, Texas.
PMID:
39233226
DOI:
10.1016/j.oret.2024.08.021
No abstract available
Keywords:
Aflibercept; Anti-VEGF; Bevacizumab; Ranibizumab; Retina.